Ivabradine Treatment to Prevent Anthracycline-Induced Cardiotoxicity: A Randomized Clinical Trial

Stephanie Itala Rizk,Isabela Bispo Santos da Silva Costa,Cecilia Cruz,Brunna Pileggi,Fernanda Thereza de Almeida Andrade,Thalita Barbosa Gonzalez,Cristina Salvadori Bittar,Julia Tizue Fukushima,Vinicius Caldeira Quintao,Eduardo Atsushi Osawa,Juliana Barbosa Sobral Alves,Silvia M. R. Fonseca,Diego Ribeiro Garcia,Juliana Pereira,Valeria Buccheri,Juliana Ávila,Lucas Tokio Kawahara,Cecilia Chie Sakaguchi Barros,Lucas Takeshi Ikeoka,Letícia Naomi Nakada,Mariella Fellini,Vanderson Geraldo Rocha,Eduardo Magalhães Rego,Paulo M Hoff,Roberto Kalil Filho,Giovanni Landoni,Ludhmila Abrahão Hajjar
DOI: https://doi.org/10.1101/2024.10.30.24316463
2024-11-05
Abstract:Background: Cancer therapy-related cardiac dysfunction frequently occurs in patients receiving anthracycline. Ivabradine reduces the heart rate without affecting contractility and has shown anti-inflammatory, antioxidant, and antiapoptotic effects in experimental models of cardiotoxicity. This study aims to evaluate the effect of ivabradine on cancer therapy-related cardiac dysfunction incidence in patients with lymphoma or sarcoma treated with anthracycline. Methods: This study was a prospective, randomized, and triple-blind trial. Patients starting anthracycline therapy were given either ivabradine 5 mg twice daily or placebo until 30 days after completing treatment. The primary outcome was a ?10% relative reduction in global longitudinal strain at 12 months. The secondary outcomes included 12-month clinical outcomes, a ?10% decrease in the left ventricular ejection fraction to <55%, diastolic dysfunction, and troponin T and NT-proBNP levels. Results: This study was conducted with 107 patients (51 in the ivabradine group and 56 in the placebo group). The median dose of anthracycline was 300 mg/m2 (250--300 mg/m2) in both groups. A ?10% relative reduction in global longitudinal strain at 12 months was reached in 57% of the ivabradine group and in 50% of the placebo group (OR 1.32, 95% CI: -0.612.83, p=.477). Fewer patients in the ivabradine group than in the placebo group had troponin T levels ?14 ng/L [16 (39.0%) vs. 23 (62.2%), p=0.041] at 6 months. There were no differences in the other secondary outcomes. Conclusions: A fixed 10 mg/day dose of ivabradine does not protect cancer patients against anthracycline cardiotoxicity.
What problem does this paper attempt to address?